Anakinra for rheumatoid arthritis
M Mertens, JA Singh - Cochrane database of systematic …, 2009 - cochranelibrary.com
M Mertens, JA Singh
Cochrane database of systematic reviews, 2009•cochranelibrary.comBackground In the past decade, a novel class of therapies directed against specific
cytokines implicated in the disease process of rheumatoid arthritis (RA), called the'Biologics'
have greatly improved and expanded treatment for RA. Anakinra is an interleukin‐1 receptor
antagonist that is currently FDA‐approved for moderate‐severe RA that has been
unresponsive to initial disease‐modifying anti‐rheumatic drugs (DMARD) therapy.
Objectives To evaluate the clinical effectiveness and safety of anakinra in adult patients with …
cytokines implicated in the disease process of rheumatoid arthritis (RA), called the'Biologics'
have greatly improved and expanded treatment for RA. Anakinra is an interleukin‐1 receptor
antagonist that is currently FDA‐approved for moderate‐severe RA that has been
unresponsive to initial disease‐modifying anti‐rheumatic drugs (DMARD) therapy.
Objectives To evaluate the clinical effectiveness and safety of anakinra in adult patients with …
Background
In the past decade, a novel class of therapies directed against specific cytokines implicated in the disease process of rheumatoid arthritis (RA), called the'Biologics' have greatly improved and expanded treatment for RA. Anakinra is an interleukin‐1 receptor antagonist that is currently FDA‐approved for moderate‐severe RA that has been unresponsive to initial disease‐modifying anti‐rheumatic drugs (DMARD) therapy.
Objectives
To evaluate the clinical effectiveness and safety of anakinra in adult patients with rheumatoid arthritis.
cochranelibrary.com